$Novo-Nordisk A/S(NVO)$  Novo Nordisk is deeply undervalued, trading at a forward P/E of 14, despite 20%+ top and bottom-line growth and dominant weight-loss market share. The anti-obesity market is set to grow nearly 10x by 2035; Novo's 71% international share and strong R&D position it for outsized gains. Current valuation reflects excessive pessimism—NVO is oversold, with profitability and growth far outpacing sector averages, making this a rare buying opportunity. I rate Novo Nordisk a Strong Buy with a $110 price target in 12–18 months, supported by robust fundamentals and powerful industry tailwinds.

$Lululemon Athletica(LULU)$   International sales, especially in China, are accelerating and now comprise over a quarter of revenue, offsetting U.S. weakness and providing a path for future LULU growth. Lululemon maintains rich gross margins in the high 50s and holds hefty cash reserves, giving flexibility for buybacks or growth initiatives. Despite recent missteps and macro headwinds, I see more upside in this cheap rebound play (at just ~13x ex-cash P/E) than in expensive large-cap tech stocks at peak valuations.

Now is an attractive entry point for long-term investors. Escalating competition in China's food delivery is expanding the market, validating Meituan's moat, and strengthening its user base despite near-term margin pressure. Emerging segments like Instashopping and in-store services are scaling rapidly, diversifying Meituan's business and deepening consumer trust beyond food delivery. While margins may remain pressured short-term due to subsidies, I expect profitability and multiples to rebound as competition normalizes by FY26.

GLD and gold in general have surged higher in recent weeks. But gold is cyclical. I prefer to express my gold position through options alone, or via an option collar. I provide timely insight on those here. The "golden collar" involves buying puts and selling covered calls on GLD to set profit and loss boundaries after the recent rally. This is as good a time as I've seen for investors to learn how to use options responsibly and with confidence, given these unique market conditions.

$Berkshire Hathaway(BRK.B)$   Berkshire Hathaway's recent stock purchases signal confidence in undervalued opportunities amidst elevated market valuations. The conglomerate trimmed Apple and Bank of America holdings, but maintains conviction in their long-term moats, while initiating a new position in UnitedHealth. Berkshire's massive $344B cash hoard offers significant firepower to accumulate on selective undervalued opportunities, and future stock buybacks. While a lack of near-term catalysts could prolong its consolidation, I view it as an opportunity for investors to load up while the market remains myopic on Berkshire stock.

Broadcom reportedly gains OpenAI as a new qualified XPU customer, spurring a reacceleration in the FY 2026 outlook. The market has already quickly lifted its optimism on the deal, as Broadcom progresses with another hyperscale-level customer win. Yet, with custom chips becoming a more critical growth driver for AVGO, how many more OpenAI-level customers can Broadcom depend on? Serious questions about whether AVGO's frothy valuations still have much further room to go must now be contemplated. I urge investors who haven't joined the party to think thrice about jumping on board

Bitcoin's bullish outlook is supported by Trump's election and increasing institutional and corporate adoption, indicating a sustained long-term uptrend beyond cyclical patterns. Despite a 90% YTD rise, Bitcoin remains below its inflation-adjusted all-time high, with recent progress and future catalysts yet to be fully priced in. Trump’s pro-crypto stance, including potential regulatory reforms and initiatives like a US Sovereign Bitcoin Reserve, could significantly boost Bitcoin's adoption and price. Risks include regulatory uncertainty and the challenge of achieving bipartisan support for pro-crypto legislation, which could impact Bitcoin's adoption and price trajectory.

$SentinelOne, Inc(S)$   SentinelOne delivered strong revenue growth and raised full-year guidance, but GAAP profitability remains elusive compared to peers like CrowdStrike. Despite competitive pressures and slowing growth, the stock's current 6x sales valuation is attractive amid renewed investor interest in software stocks.  SentinelOne is a "Buy," as sector rotation into software outweighs concerns about decelerating growth and margin challenges. Risks remain from stronger rivals and uncertain profitability, but the company's strong balance sheet and growth profile support a positive outlook.

The S&P 500 trades at 6,643.71, holding above 20-day EMA support despite last week’s 0.31% decline. Stronger U.S. data dampened Fed cut bets, with yields above 4.15% weighing on equities. The jobs report will decide if the index breaks the 6,700 resistance or risks a retracement toward 6,450.

$UnitedHealth(UNH)$  Berkshire Hathaway’s UnitedHealth Group Incorporated share purchase signals confidence in a sector where it has deep operational expertise. UnitedHealth remains systemically vital; no one, or possibly collection of competitors can absorb its market share or infrastructure. UNH stock trades ~56% below all-time high, offering ~127% upside potential if the shares return to those levels plus a growing dividend yield. Despite sector downgrades, UNH’s free cash flow covers its dividend with room to spare.

The S&P 500 notched two new highs last week, continuing a strong uptrend since October 2022, despite macroeconomic uncertainties. Tech and high-beta stocks led the rally, while defensive sectors like Consumer Staples and Utilities lagged; growth outperformed value. Investors rotated out of foreign markets, REITs, and gold, favoring NASDAQ, blockchain, crude oil, and cyclical equities over the past two weeks. Valuations are approaching 1999 levels, raising caution about future returns as richly valued stocks may not sustain recent performance highs.

$Lululemon Athletica(LULU)$   Store expansion, especially internationally, and superior ROIC per store versus peers indicate a long runway for growth before saturation. Cyclical industry headwinds and macro uncertainty have weighed on results, but improving consumer sentiment and potential rate cuts could drive a rebound. My DCF and comps analysis support a $259 price target, representing 26% upside; but

$ARK Innovation ETF(ARKK)$  Market remains bullish across indexes, with no clear signs of bull traps or bearish reversals as Q3 ends. Valuations are elevated, especially among Mag 7 and S&P 500, nearing historical peaks seen before past downturns. Institutional selling and climax top indicators suggest rising downside risks, but price action still favors further rally into Q4. Continue monitoring for shifts in momentum; maintain bullish bias unless clear downside signals emerge.

$Viking Therapeutics(VKTX)$  charging like the Vikings with this position -   I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts

The reality as I see it now is that TSLA's robotaxi rollout is on track, with public launches and regulatory approvals. Short-term regulatory and competitive hiccups in the robotaxi business are rather immaterial so long as TSLA progresses toward the end goal of unlocking this trillion dollar opportunity. The Q3 print may have automotive margins pressure which is likely to continue into Q4 as EV credits fall off. But again, don't focus too much on the automotive business. TSLA stock's valuations make sense if we look at the value potential in robotaxis and humanoid robots. The technicals also align bullish.

$Intel(INTC)$  After a 30% gain on my entry,, I'm re-evaluating Intel under its new CEO. The company is at a critical juncture with a dramatic strategy shift ongoing.

Broadcom secured a $10 billion XPU order, driving a record $110 billion backlog and providing strong topline visibility. AI semiconductor revenue surged 63% YoY in Q3 to $5.2 billion, with Q4 forecasted at 66% growth. EBITDA margins remain robust at 65%+, delivering $10.7 billion in adjusted EBITDA and $7 billion in Q3 free cash flow. Valuation trades at ~50x forward P/E and 26x EV/Sales, significantly above sector medians and historical averages. Extreme client concentration with top five customers contributing ~40% of revenue creates potential single-point failure risks

The August jobs report confirms a significant labor market slowdown, with only 22,000 jobs created, the U-3 unemployment rate rising to 4.3%, and broader unemployment rising to 8.1%. Nominal GDP growth is decelerating, as indicated by the Aggregate Weekly Payrolls index, giving the Fed a green light for a September rate cut. The yield curve is bull steepening, driven by falling 2-year rates; further steepening is likely but may be limited by Fed Funds futures pricing. Despite weak job data, the 10-year rate may not fall much below 4% unless economic data worsens further, signaling limited downside for long-term yields

Gold trades around $4,100 as Fed rate cut bets offset easing trade risks. Investors await U.S. CPI data for clues on the Fed’s policy path. Support seen near $4,000, with resistance around $4,380.

Tesla, Inc. stock has surged to levels last seen in January 2025, as bulls returned with a buying fervor not seen in recent months. TSLA's future growth narrative centers on energy storage, robotaxis, and Optimus humanoid robotics, though these remain nascent contributors to profitability. Musk's unprecedented $1 trillion compensation package sets extremely high operational and market cap milestones, making current valuations challenging to justify. Currently priced with no room to disappoint!